LEADER 05494nam 2201297z- 450 001 9910566462603321 005 20231214133246.0 035 $a(CKB)5680000000037755 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81051 035 $a(EXLCZ)995680000000037755 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRegional Intestinal Drug Absorption$eBiopharmaceutics and Drug Formulation 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (238 p.) 311 $a3-0365-3658-2 311 $a3-0365-3657-4 330 $aThe gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e.g., the surrounding pH, fluid composition, transporters expression, metabolic enzymes activity, tight junction resistance, different morphology along the GIT, variable intestinal mucosal cell differentiation, changes in drug concentration (in cases of carrier-mediated transport), thickness and types of mucus, and resident microflora. Each of these variables, alone or in combination with others, can fundamentally alter the solubility/dissolution, the intestinal permeability, and the overall absorption of various drugs. This is the underlying mechanistic basis of regional-dependent intestinal drug absorption, which has led to many attempts to deliver drugs to specific regions throughout the GIT, aiming to optimize drug absorption, bioavailability, pharmacokinetics, and/or pharmacodynamics. In the book "Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation" we aim to highlight the current progress and to provide an overview of the latest developments in the field of regional-dependent intestinal drug absorption and delivery, as well as pointing out the unmet needs of the field. 517 $aRegional Intestinal Drug Absorption 606 $aMedicine$2bicssc 606 $aPharmaceutical industries$2bicssc 610 $abioequivalence 610 $aBiopharmaceutics Classification System 610 $ain vitro 610 $adissolution test 610 $apravastatin 610 $aoral absorption 610 $ain silico modeling 610 $aGastroPlus 610 $aPhoenix WinNonlin 610 $apharmacokinetics 610 $aclinical studies 610 $aibuprofen 610 $amanometry 610 $agastrointestinal 610 $amechanistic modeling 610 $aPBPK 610 $aPBBM 610 $adisintegration 610 $adissolution 610 $aenteric-coated 610 $aICH 610 $aquality control 610 $aregional intestinal permeability 610 $apermeation enhancers 610 $aabsorption-modifying excipients 610 $aoral peptide delivery 610 $aintestinal perfusion 610 $apharmaceutical development 610 $acontrolled release drug product 610 $abiopharmaceutics classification system 610 $adrug solubility 610 $adrug permeability 610 $alocation-dependent absorption 610 $asegregated flow intestinal model (SFM) 610 $atraditional model (TM) 610 $aroute-dependent intestinal metabolism 610 $afirst-pass effect 610 $adrug-drug interactions 610 $aDDI 610 $ain vitro in vivo extrapolations 610 $aIVIVE 610 $azero-order absorption 610 $afirst-order absorption 610 $acombined zero- and first-order absorption 610 $atransit compartment absorption model 610 $ain situ perfusion 610 $amicrodevices 610 $ashape 610 $amucoadhesion 610 $acolon absorption 610 $anutrient digestion 610 $anutrient absorption 610 $agastrointestinal hormone 610 $apostprandial glycaemia 610 $aenergy intake 610 $aregion of the gut 610 $aobesity 610 $atype 2 diabetes 610 $aFranz?PAMPA 610 $aBCS drugs 610 $abiomimetic membrane 610 $aFranz cell 610 $apassive drug transport 610 $aBCS class IV drugs 610 $asegmental-dependent intestinal permeability 610 $aintestinal absorption 610 $aoral drug delivery 610 $abiopharmaceutics 610 $aphysiologically-based pharmacokinetic (PBPK) modeling 610 $afurosemide 610 $aintestinal permeability 610 $ahuman colon carcinoma cell layer (Caco-2) 610 $ahierarchical support vector regression (HSVR) 610 $adrug absorption 610 $adrug solubility/dissolution 610 $aregional/segmental-dependent permeability and absorption 615 7$aMedicine 615 7$aPharmaceutical industries 700 $aGonzalez-Alvarez$b Maria Isabel$4edt$01330868 702 $aDahan$b Arik$4edt 702 $aGonzalez-Alvarez$b Maria Isabel$4oth 702 $aDahan$b Arik$4oth 906 $aBOOK 912 $a9910566462603321 996 $aRegional Intestinal Drug Absorption$93040001 997 $aUNINA